From AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial:

An investigational treatment for overactive bladder conducted by AbbVie using technology from UroGen Pharma failed a Phase 2 study.
An investigational treatment for overactive bladder conducted by AbbVie using technology from UroGen Pharma failed a Phase 2 study.

Image: iStock/C5Media